The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thai, T.-H.
Right arrow Articles by Kearney, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thai, T.-H.
Right arrow Articles by Kearney, J. F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2004, 173: 4009-4019.
Copyright © 2004 by The American Association of Immunologists

Distinct and Opposite Activities of Human Terminal Deoxynucleotidyltransferase Splice Variants1

To-Ha Thai2,*,{dagger} and John F. Kearney3,*,{dagger}

* Division of Developmental and Clinical Immunology, and {dagger} Department of Microbiology, University of Alabama, Birmingham, AL 35294


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Evidence for potential human TdT (hTdT) isoforms derived from hTdT genomic sequences led us to identify the short isoform (hTdTS), as well as mature long transcripts containing exon XII (hTdTL1) and another including exon VII (hTdTL2) in lymphoid cells. Normal B and T lymphocytes express exclusively hTdTS and hTdTL2, whereas hTdTL1 expression appears to be restricted to transformed lymphoid cell lines. In in vitro recombination and primer assays, both long isoforms were shown to have 3'->5' exonuclease activity. Overexpression of hTdTS or hTdTL2 greatly reduced the efficiency of recombination, which was reverted to normal levels by the simultaneous expression of both enzymes. Therefore, alternative splicing may prevent the adverse effects of unchecked elongation or diminution of coding ends during V(D)J recombination, thus affecting the survival of a B or T cell precursor during receptor gene rearrangements. Finally, the newly discovered hTdT isoforms should be considered in future screening of human leukemias.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
To date, Ag receptors on B (Igs) and T cells (TCRs) of all higher vertebrate taxa examined, including mammals (1), birds (2), reptiles (3), amphibians (4), teleosts (5), and cartilaginous fish (6) are generated through V(D)J recombination (7). V(D)J recombination, which occurs at specific stages of B and T cell development (8), is a mechanism by which the Ag-binding region or the CDR3 of Ig H and L chains and TCRs is generated through combinatorial rearrangements of the V, D, and J gene segments. The V(D)J recombination reaction is initiated by lymphoid-specific MLR RAG-1 and RAG-2 proteins and is completed by ubiquitously expressed nonhomologous end-joining and double-stranded break repair proteins, including Ku70, Ku86, the catalytic subunit of DNA-dependent protein kinase, XRCC4 and DNA ligase IV, and Artemis (9, 10, 11, 12, 13, 14, 15). Although these proteins are required for the production of Igs and TCRs, most of the junctional diversity was shown to be contributed by nontemplated (N)4 addition and nucleotide deletion at V(D)J joins (16, 17).

TdT is a nuclear enzyme belonging to the X family of polymerases. The sequence of all members of this family contains the conserved X signature domain that mediates nucleotide interaction. The short isoform of mouse TdT (mTdTS; 509 aa long) is responsible for N addition at coding joins (CJs) (18, 19, 20, 21, 22). We showed that the long isoform of mTdT (mTdTL; 529 aa long) has 3'->5' exonuclease (exo) activity capable of catalyzing the deletion of nucleotides from coding ends with either 3' or 5' extensions, but not from blunt signal ends (23). Recently, Artemis has been shown to have both endonuclease and exo activities, and the suggestion that there may be redundant exos has been confirmed by the residual exo activity observed in an Artemis-deficient ES cell line (12, 13, 14, 15).

In vertebrates where V(D)J recombination occurs, the TdT gene (Dntt) is conserved (24, 25, 26, 27). Moreover, N addition and nucleotide deletion from coding ends contribute to the majority of junctional diversity in Igs and TCRs of these respective species; however, long isoforms of TdT (TdTLs) have only been identified in mice and cattle (28). The failure to identify TdTL isoforms in other species may be due to their lack of sequence homology to one another.

Studies thus far, show that the human Dntt is expressed in fetal life, and is generally restricted to T and B cell progenitors in the thymus and the bone marrow, although there may be exceptions (29, 30, 31). In addition to its role in diversifying Ag receptors, human TdT (hTdT) has been used as a marker in the diagnosis of certain human leukemias (32, 33, 34). The consequences of hTdT overexpression in malignancies have yet to be determined.

To determine whether the long isoform of hTdT (hTdTL) exists, and to gain insight into its functions during V(D)J recombination and leukemogenesis, the genomic sequence of the hTdT gene, located on chromosome 10, was examined. This search revealed that, in human, as in cattle, three potential TdT isoforms exist: theshort isoform (hTdTS), and two long isoforms 1 (hTdTL1) and -2 (hTdTL2). The deduced amino acid sequences of hTdTL1 and hTdTL2 are highly homologous to those of the long isoform of bovine TdTL1 (bTdTL1) and bTdTL2. The generation of expression cDNA clones of hTdTL1 and hTdTL2 in vitro permitted us to show that hTdTL1 and hTdTL2 can localize to the nucleus, and like hTdTS, hTdTL2 transcripts are detected during B and T cell development. hTdTL1 transcripts were not detectable, yet both hTdTL1 and hTdTL2 have 3'->5' exo activity in recombination assays. However, hTdTL1 could be detected in transformed lymphoid cells. Moreover, in a standard recombination assay, the overexpression of hTdTS or hTdTL2 adversely affects the recombination efficiency, which is rescued by the concomitant expression of the two enzymes in the same cell.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Human samples and Abs

The Birth Defects Research Laboratory at University of Washington (Seattle, WA) provided human thymi, and University of Alabama at Birmingham Cancer Center Tissue Procurement program provided human bone marrows. All Abs used for FACS were purchased from BD Pharmingen (San Diego, CA.).

RT-PCR

Total RNA from sorted B cells was prepared with Tri-Reagent (Molecular Research Center, Cincinnati, OH), treated with DNase, and reverse transcribed with oligo(dT) primers. TdTS, TdTL1, or TdTL2 sequences were amplified from cDNA with the following primers: forward primers, 5'-CCGAAGACTCCACCAATTGCTG-3' and 5'-GCTGGTTAAAGAGGCTGTCTGG-3'; hTdTS reverse (R1), 5'-CAGAAATCCTGCTTTCTGC-3'; hTdTL1 reverse (R2), 5'-CTGAAAACATAACAAGAAATATGTGC-3' (within the L1 insert); and hTdTL2 reverse primer (R3) 5'-GACCCGACCAGCCCATAGCAAC-3' (within the L2 insert). Conditions were as described (23). PCR conditions were 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min. The human cell line EU12 was a gift from H. Findley (Emory University School of Medicine, Atlanta, GA). The cell lines 697 and nalm 16 were purchased from American Type Culture Collection (Manassas, VA).

Generation of hTdTS, hTdTL1, and hTdTL2 cDNAs

cDNAs were generated by PCR insertion mutagenesis with the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) with modifications. The L1 or the L2 insert sequence was inserted into anhTdTS cDNA obtained from M. Ehrenstein (Division of Medicine, Royal Free and University College, London, U.K.) by PCR with the following primers: L1 forward, 5'-TGCACATATTTCTTGTTATGTTTTCAGAGGATATTCCTCAAAGCAGAAAG-3'; L1 reverse, 5'-CTGAAAACATAACAAGAAATATGTGCACTTGGTCTTGTCATATA AAGC-3'; L2 forward, 5'-CCTAAAAGTCATTGTTGCTATGGGCTGGTCGGGTCGTGGATTTCTGTATTATGAAGACCTTG-3'; and L2 reverse, 5'-CATAGCAACAATGACTTTTAGGAGAGACAATTTACCTGCTTTCTGCATTCGTGTAAATTTC-3'. PCR conditions were identical with those described for RT-PCR above. Resulting cDNAs were analyzed to verify the integrity of their sequence.

Immunoblots

Protein immunoblots were performed by standard methods. hTdT isoforms were probed with a commercial rabbit polyclonal Ab against bTdT (Supertechs, Bethesda, MD) and then detected with a HRP-conjugated goat anti-rabbit IgG Ab (Southern Biotechnology Associates, Birmingham, AL). Blots were developed with ECL Plus (Amersham Pharmacia Biotech, Piscataway, NJ).

Immunohistochemistry

Transfected cells recovered from recombination assays were stained as follows. Briefly, cytocentrifuge smears of transfected cells were dried, fixed in absolute methanol, stained for TdT expression with the same Ab used for immunoblots, and then developed with an Alexa 488-coupled goat anti-rabbit IgG Ab (Molecular Probes, Eugene, OR). F-actin filaments were stained with phalloidin conjugated to Alexa Fluor 546 at 5–10 U (Molecular Probes). Fluorescent images were captured with a Leica/Leitz (Deerfield, IL) DMRB microscope.

Primer modification assay

Purified primers (Invitrogen Life Technologies, Carlsbad, CA) were labeled with [{gamma}-32P]ATP at the 5' end with T4 polynucleotide kinase (New England Biolabs, Beverly, MA). Labeled primers were then purified with Bio-Spin 6 chromatography columns (Bio-Rad, Hercules, CA). To generate dsDNA, labeled primers were annealed with complementary strands. Primers (6 pmol) were incubated with purified TdTS or TdTL (250 nM each, dialyzed against Tris-acetate buffer at pH 7.2 and 10% glycerol) in reaction buffer (0.2 M potassium cacodylate at pH 7.2, 4 mM MgSO4, 0.1 mM DTT, 100 µg/ml BSA, 10 µM ZnSO4, and 50 µM dNTPs) for 30–90 min at 37°C. The reaction was terminated by the addition of stop buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol FF). Samples were resolved on denaturing acrylamide gels and autoradiograms were obtained with Kodak (Rochester, NY) x-ray films.

Protein expression

To express N-terminal GST-tagged fusion proteins, hTdTS, hTdTL1, or hTdTL2 cDNA was cloned into the pGEX-4T-1 vector (Amersham Pharmacia Biotech). Expression was induced with 0.1 mM isopropyl {beta}-D-thiogalactoside (Roche, Indianapolis, IN) for 3 h at 25–30°C. Fusion proteins were purified with glutathione Sepharose 4B (Amersham Pharmacia Biotech). For mammalian expression, hTdTS, hTdTL1, or TdTL2 cDNA was subcloned into pcDNA 1.1/Amp vector (Invitrogen Life Technologies).

Recombination assays

Assays were done as described (23). Briefly, cells were transfected with Fugene 6 Transfection Reagent, according to the manufacturer’s suggestions (Roche). Each subconfluent T-25 flask (~106 cells) was cotransfected with 1.5 µg of recombination substrate, 1.8 µg of truncated (core) RAG-1, 2.1 µg of truncated (core) RAG-2, and 1–2 µg of TdTS- or TdTL-pcDNA 1.1. After 48 h, DNA was recovered with the Hirt method (23). PCR products were purified with the QIAquick PCR purification kit (Qiagen, Valencia, CA) instead of treating with ExoI and alkaline phosphatase, and purified products were sequenced with primer DR99, which primed the coding ends.

GenBank numbers

GenBank accession numbers are as follows: mTdTL, accession no. AF316014; bTdTL, accession no. A23595; and human chromosome 10, accession no. 10834424.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Identification of three TdT isoforms in human

We have recently shown that mTdTL has 3'->5' exo activity. However, TdTL isoforms have only been identified in mice and cattle, although nucleotide deletion during receptor gene rearrangements is observed in the many vertebrates in which V(D)J recombination has been studied. To resolve this issue, we examined the hTdT genomic sequence to identify hTdTL isoforms. A search of the National Center for Biotechnology Information (NCBI) database revealed that, like that of bovine, the human Dntt has two additional exons. The first extra exon is 27 nt long, whereas the second is 51 nt long (Fig. 1A). The first and second extra exons could potentially encode 9-aa (L1) and 17-aa (L2) peptide fragments, respectively (Fig. 1B). An examination of the mTdT genomic sequence, obtained through the Celera database, also revealed the presence of an additional exon, which could potentially encode a second mTdTL (mTdTL2), the transcript of which was detected in the mouse cell line HTX-1 (T.-H. Thai and J. F. Kearney, manuscript in preparation). The deduced amino acid sequences of hL1 and hL2 inserts were highly homologous to those of bovine: hL1/bL1 had 67% aa identity, and hL2/bL2 had 77% aa identity (Fig. 1B). In addition, human and bovine L1 inserts were half the size of mL1. Moreover, all three exo core motifs were found in the hTdT sequence, and Asp residues shown to confer the majority of exo activity to mTdTL (23) were also conserved (Fig. 1C; amino acids important for activity are in green). Based on these results and those of others (35), the genomic organization of human and bovine TdT genes was deduced (Fig. 1D); L1 and L2 inserts were encoded by exons XII and VII, respectively. The inclusion of the L1 and L2 inserts in mature transcripts gave rise to TdTL1 and TdTL2 isoforms, respectively. Thus far, a transcript containing both L1 and L2 inserts has not been detected in either human or mouse (T.-H. Thai, unpublished observations). The Dntt organization of these two species was highly conserved (Fig. 1D). The predicted exon-intron boundaries for both exons were deduced from the hTdT genomic sequence (Table I). In both cases, the nearly invariant dinucleotides GT at the 5' splice site (donor site) and AG at the 3' splice site (acceptor site) were conserved. Because exons VI/VII and XII/XIII were not separated by any introns, their donor and acceptor sites would be considered cryptic.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 1. Genomic and deduced amino acid sequence analyses of hTdT splice variants. A, The hTdT genomic sequence was retrieved from NCBI and Celera human genome database, and aligned with mouse and bovine TdT sequences to identify L1 and L2 inserts. Intron-exon boundaries are shown in Table I. B, The deduced amino acid sequences of L1 and L2 inserts from all three species were aligned. L1 and L2 inserts are in red and blue, respectively; dashed lines indicate missing residues. C, Amino acid sequence alignment of mouse, rat, bovine, and human TdTL isoforms was done to identify exo core motifs; conserved residues are in green. The third exo motif is underlined to show its upstream position proximal to the L1 insert (in red). D, Genomic organization of bovine and human TdT gene was deduced based on sequence analyses and data from others (35 ); newly identified exons VII and XII are represented by slashed boxes. E, Domain structure of the hTdT protein. Amino acid sequences surrounding the inserts are identical between hTdTL1 (top) and hTdTL2 (bottom); thus, the domains are conserved.

 

View this table:
[in this window]
[in a new window]
  		Table I. Exon-intron splice-junction sequences of the hTdT gene

 
Like other DNA-modifying proteins such as BRCA-1, all three hTdT isoforms contain one BRCA-1 C-terminal (BRCT) domain in the N terminus, which is thought to mediate protein-protein and protein-DNA interactions (36, 37). Moreover, all domains important for TdT activity, such as nucleotide, DNA, and cation binding are conserved in all three hTdT isoforms (38, 39, 40, 41). In addition, three cAMP-dependent phosphorylation sites are also present, as well as the putative tyrosine phosphorylation motif (Fig. 1E).

Regulated expression of hTdTL1 and hTdTL2

Because hTdTL1 and hTdTL2 were identified from hTdT genomic sequence, it was necessary to determine whether they were transcribed in lymphoid cells. During human B cell development, IgH chain genes rearrange at the pro-B stage where N addition and nucleotide deletion occur. Successful production of the H chain is followed by L chain gene rearrangement at the pre-B stage (42). hTdTL1, hTdTL2, and hTdTS expression during these stages was assessed by RT-PCR. Total RNA was prepared from pro-B (CD34+CD19+surface (s)IgM–), pre-B (CD34–CD19+sIgM–), and mature B cells (CD34–CD19+sIgM+) sorted from human adult bone marrow. Transcripts of hTdT isoforms were detected in the pro-B population; hTdTS expression was most abundant, hTdTL2 expression was intermediate, and hTdTL1 was lowest (Fig. 2A). This population may contain small numbers of class-switched B cells, but TdT is not expressed in this mature population (J. F. Kearney, unpublished observations). In contrast, only hTdTS and hTdTL2 mRNAs were present in the pre-B cell stage (Fig. 2A). As expected, none of the isoforms were seen in the mature B cell population (Fig. 2A). These results show that the expression of hTdT isoforms is regulated during B cell development. However, this ordered pattern of expression was altered in transformed cell lines, because along with the other isoforms, hTdTL1 was detected in the human cell line 697 representative of the pre-B cell stage (Fig. 2A), where it is normally not detected (A).



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2. Regulated expression of hTdT splice variants during B and T cell development. A, Adult human bone marrow pro-B and pre-B cells were isolated by FACS with forward-light scattering and the markers CD19+IgM–CD34+ and CD19+IgM–CD34–, respectively. Mature B cells were identified as CD19+IgM+CD34–. Left panel, RT-PCR products were generated from sorted bone marrow subpopulations with hTdT isoform-specific primers. Right panel, RT-PCR products from human cell lines: Nalm 16, pro-B stage; EU12, pro-pre-B stage; 697, pre-B stage. B, Fetal DN (CD4–CD8–), DP (CD4+CD8+), CD8+, and CD4+ thymocytes obtained from days 91 and 111 thymi were purified by FACS with forward-light scattering and the markers CD3, CD8, and CD4. RT-PCR products were generated with hTdT isoform-specific primers. C, RT-PCR analyses were performed to detect human RAG-1 and RAG-2 genes in the same fetal thymocyte subpopulations as defined in B. D, In adult thymocytes, both hTdTS and hTdTL2 were expressed at similar levels, in all stages of T cell development. hRAG2 transcripts were readily seen in the single-positive populations, whereas hRAG1 was not present, perhaps due to transcript instability or aging. E, All three hTdT isoform transcripts were detected in Molt-4, Cem-6, and Jurkat human T cell lines by RT-PCR. F, Alternative splicing patterns of human, bovine, and rat Dntt were deduced based on genomic sequences and RT-PCR analyses. Red and blue lines indicate exclusion and inclusion of exon VII, respectively. Green line depicts constitutive exclusion of exon XII during normal lymphocyte development; however, inclusion of this exon could occur in transformed cells.

 
To date, the expression of hTdT isoforms during normal human thymocyte development has not been formally assessed. Similar to adult bone marrow pre-B cells, hTdTL1 was not detected in fetal thymocytes at any age (Fig. 2B). However, hTdTL1 was detected in transformed T cell lines (Fig. 2E). In a semiquantitative RT-PCR assay, both hTdTS and hTdTL2 were expressed in all stages of thymocyte development (double-negative (DN; CD4–CD8–), double-positive (DP; CD4+CD8+), CD4+, and CD8+ thymocytes), as well as in transformed cell lines (Fig. 2, B and E, respectively). The level of hTdTL2 transcripts was consistently higher than that of hTdTS. At fetal day 91, all four populations studied (DN, DP, CD4+, and CD8+ thymocytes) expressed less hTdTS than hTdTL2, and this level of differential expression persisted until fetal day 111, albeit slightly less pronounced. Moreover, TdT proteins are readily detected in the respective thymocyte subpopulations by FACS analyses using pan-TdT-specific mAbs (data not shown). To verify the developmental stages of sorted fetal thymocytes, the expression of RAG genes was analyzed. DP cells expressed the highest levels of RAG-2 mRNA, whereas RAG-1 expression appeared to be stage and age independent. Moreover, there appeared to be a higher level of RAG-2 transcripts in the single CD4+ and CD8+ populations in 91-day-old fetal thymocytes compared with those from 111 days (Fig. 2C). In contrast, both hTdTS and hTdTL2 were expressed at similar levels in all stages of adult thymocyte development (Fig. 2D). hRAG1 expression was not detectable in adult thymocytes, whereas hRAG2 transcripts were present, especially in the single-positive populations (Fig. 2D). The absence of hRAG1 in adult thymocytes may be due to transcript instability and/or age-dependent expression.

Therefore, in normal human B and T cells, exon XII of hTdT gene is always excluded, whereas exon VII can be included (generating hTdTL2) or excluded (generating hTdTS). In contrast, bovine exons XII and VII can be included (producing bTdTL1 and bTdTL2, respectively) or excluded (producing bTdTS) (28) (Fig. 2F). Thus, alternative splicing, which appears to be species specific, seems to regulate human and bovine TdT isoforms expression.

Nuclear localization of hTdTL1 and hTdTL2

We have demonstrated that mature transcripts of both hTdTL isoforms are made in normal and transformed lymphoid cells; however, their activities and cellular localization are not known. To carry out these studies, respective cDNAs were generated by PCR insertion mutagenesis. Sequence analyses of hTdTS, hTdTL1, and hTdTL2 cDNAs revealed no changes when compared with both the NCBI and Celera genomic sequences (data not shown).

To establish whether the conserved nuclear localization motifs in hTdTL1 and hTdTL2 sequences do indeed mediate their localization into the nucleus, all three hTdT isoforms, subcloned into the pcDNA1.1+ mammalian expression vector, were expressed in the human embryonic kidney cell line 293T. After transfections, protein expression and cellular localization were verified by immunofluorescence using a rabbit polyclonal Ab raised against bTdT. hTdTL1 and hTdTL2, as well as hTdTS, localized in nuclei of 293T cells transfected with the respective plasmid (Fig. 3, green), whereas actin filaments (stained with phalloidin) localized mainly in the cytoplasm (Fig. 3, red). All three isoforms exhibited punctuated nuclear staining similar to that observed in normal lymphocyte precursors.



View larger version (95K):
[in this window]
[in a new window]
  		FIGURE 3. Nuclear localization of hTdTS, hTdTL1, and hTdTL2. 293T cells were transiently transfected with plasmids encoding respective cDNAs. After 48 h, cytospin preparations of cells were stained. hTdT isoforms (green; stained with a rabbit anti-bTdT polyclonal Ab) localized mainly in the nucleus, and F-actin filaments (red; stained with phalloidin conjugated to Alexa Fluor 546) localized primarily in the cytoplasm. Mock, Empty vector.

 
In vitro activities of hTdTL isoforms

The presence of hTdT isoforms in the nucleus of normal lymphocytes suggests that they may function as DNA-modifying enzymes. To test this hypothesis, primer modification assays were done with purified TdTS- and TdTL-GST fusion proteins. Samples were resolved on 7 or 15% denaturing acrylamide gels. As expected, hTdTS efficiently catalyzed the addition of dNTPs to the 21-bp ssDNA (Fig. 4, lane 1). In contrast, hTdTL1 and -2 showed 3'->5' exo activity, producing species progressively smaller than the original 21-bp primer (Fig. 4, lanes 2 and 3); the primer was not modified by buffer alone (lane 4).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 4. Exo activity of hTdTL1 and hTdTL2. Primer modification assays were done to show that hTdTL1 and hTdTL2 possess 3'->5' exo with a variety of DNA substrates. ssDNA labeled at the 5' end was used in lanes 1, 2, 3, and 4; 5'-labeled dsDNA with 3' extensions was used in lanes 5, 6, 7, and 8; 5'-labeled dsDNA with 5' extensions or 3' recess was used in lanes 9, 10, 11, and 12; 5'-labeled dsDNA with blunt ends was used in lanes 13, 14, 15, and 16. hTdTS samples were resolved on 7% denaturing acrylamide gels (lanes 1, 5, 9, and 13); hTdTL1 (lanes 2, 6, 10, and 14) and hTdTL2 (lanes 3, 7, 11, and 15) samples were resolved on 15% denaturing acrylamide gels. No enzyme controls were shown in lanes 4, 8, 12, and 16 (15% gel). Note that a nonspecific oligonucleotide band was seen in lanes 14 and 15, as well as the no-enzyme control (lane 16). Thus, the presence of this band could not be ascribed to any transferase activity of hTdTL1 nor hTdTL2. The transferase activity of hTdTS generates larger oligonucleotide bands, which could not be efficiently resolved on a 15% gel. hTdTL1 and hTdTL2 activity could not be clearly shown on a 7% gel due to the increasingly smaller sized bands generated by their exo activity. Arrows indicate input substrate positions.

 
During V(D)J recombination, coding and signal ends are generated as a result of RAG-1- and RAG-2-mediated DNA cleavage. Coding ends are thought to possess 3' or 5' extensions, whereas signal ends are blunt. Thus, if hTdTL1 and -2 were involved in the deletion of nucleotides from coding ends, dsDNA with 3' or 5' extensions would be expected to undergo nucleotide loss. We found that hTdTL1 and -2 efficiently degraded dsDNA with 3' extensions (Fig. 4, lanes 6 and 7, respectively), and TdTS added nucleotides to the same substrate (lane 5). dsDNA with recess 3' ends or 5' extensions were also modified by all three hTdT isoforms (Fig. 4, lanes 9–11). Moreover, dsDNA with blunt ends were similarly modified by all three isoforms (Fig. 4, lanes 13–15). The substrates were not modified in the absence of hTdT isoforms (Fig. 4, lanes 4, 8, 12, and 16). The low amount of smaller species is due to spontaneous degradation of the primers. Because the extent of transferase activity catalyzed by hTdTS was extensive, all reactions shown for hTdTS were resolved on 7% denaturing acrylamide gels. The low-percentage gels allowed better resolution of the DNA ladder, which would otherwise stay at the top of a 15% gel (data not shown). The exo activity of hTdTL1 and -2 was similarly compressed when resolved on a 7% gel (data not shown); thus, all reactions shown for hTdTL1 and -2 were resolved on 15% gels.

These data show that, in vitro, hTdTL isoforms exhibited 3'->5' exo activity with no detectable 5'->3' exo activity. Their substrate specificity included ssDNA and dsDNA with 3' or 5' extensions. Transferase activity was not observed in any reactions conducted with either hTdTL1 or hTdTL2.

In vivo activities of hTdTL isoforms

To determine whether hTdTL isoforms also exhibited exo activity in vivo, recombination assays were done (23). In these assays, expression vectors encoding the truncated active core RAG-1 and RAG-2 recombinase proteins were transiently transfected into Chinese hamster ovary (CHO) cells along with a CJ recombination substrate plasmid, with or without expression vectors encoding hTdTS, hTdTL1, or hTdTL2. CHO cells were chosen for these experiments because hRAG1 protein, and hTdTS and hTdTL isoform messages were readily detected in the human 293T cell line; therefore, in our hands, 293T cells give unacceptable background recombination (T.-H. Thai and J. F. Kearney, unpublished observations); the status of hRAG2 protein expression in 293T cells cannot be determined, because quality Abs useful for immunohistochemistry and/or immunoblots are not available. The integrity of CJs from CHO transfectants was evaluated by sequence analyses (Fig. 5, A and B). We hypothesized that, if hTdTL1 and hTdTL2 were indeed exos in vivo, CJs formed in the presence of hTdTL1 and hTdTL2 would exhibit more nucleotide loss than joins formed with hTdTS or without hTdT. Analyses of CJs from CHO transfectants supported this hypothesis. On average, 4.7 ± 0.6 nt (p = 0.0028) were deleted from coding ends in the presence of hTdTL1 and 5.7 ± 0.6 nt (p < 0.0001) in the presence of hTdTL2, whereas without hTdT or in the presence of hTdTS, only 1.9 ± 0.7 and 2.3 ± 0.3 nt were lost from coding ends, respectively (Table II and Fig. 5C). N addition was not observed for hTdTL2 in this assay; 1 sequence of 16 with 1 nt added was recovered from hTdTL1 transfectants. In addition, few sequences with palindromic (P) additions were recovered from either hTdTL1 (12%) or hTdTL2 (5%) transfectants. In contrast, considerably more sequences contained P additions in the presence of hTdTS (44%) or without hTdT (29%), suggesting that hTdTL isoforms are responsible for the removal of P nucleotides from coding ends.



View larger version (66K):
[in this window]
[in a new window]
  		FIGURE 5. Deletion of nucleotides from coding ends but not from signal ends by hTdTL1 and hTdTL2 in the standard recombination assay. A and B, Coding-end sequences were obtained from PCR products with primer DR99 (23 ). Underlined sequences are unmodified coding ends. Numbers in parentheses indicate repeated sequences recovered from multiple independent transfections, not within one transfection. No TdT, Three transfections; hTdTS, three transfections; hTdTL1, four transfections; hTdTL2, four transfections; hTdTS plus hTdTL1, three transfections; hTdTS plus hTdTL2, four transfections; hTdTS plus hTdTL1 plus hTdTL2, three transfections. C, Mean ± SEM nucleotides deleted from coding ends recovered from different transfectants. Values of p were calculated with unpaired two-tailed Student’s t tests.

 

View this table:
[in this window]
[in a new window]
  		Table II. In vivo analyses of nucleotide deletion, N addition, and P additiona

 
It is likely that, during V(D)J recombination, hTdTS and hTdTL2are present simultaneously during the formation of CJs. To recapitulate this situation, recombination assays were done in the presence of both enzymes. When hTdTS was included in the assay, the mean ± SEM nucleotide loss effected by hTdTL2 decreased from 5.7 ± 0.6 to 3.1 ± 1.0 (Table II and Fig. 5C), indicating that deletion by hTdTL2 was attenuated by hTdTS in vivo. Likewise, hTdTL1 exo activity was reduced by hTdTS, although hTdTL1 does not appear to be expressed during normal B and T cell development. The inclusion of all three isoforms did not additively lessen nucleotide loss from coding ends. The number of sequences with P additions was similar to that with (44%) or without hTdTS (29%) when isoforms were coexpressed (hTdTS plus hTdTL1, 33%; hTdTS plus hTdTL2, 30%; all three isoforms, 44%). It is also noteworthy to point out that the average length of N nucleotides was not decreased by the simultaneous expression of hTdTS with either hTdTL1 or hTdTL2 (average nucleotides added with hTdTS alone, 2.1; with hTdTS plus hTdTL1, 1.2; with hTdTS plus hTdTL2, 2.2). These observations suggest that, in this situation, deletion may occur before addition.

In vitro as well as in vivo, hTdTL1 and hTdTL2 behave as exos capable of catalyzing nucleotide loss from coding ends during recombination. However, in normal B and T cell progenitors,hTdTL1 expression is suppressed by constitutive exclusion of exon XII via alternative splicing mechanisms. Therefore, the propensity to exclusively express one exo, hTdTL2, suggests that perhaps the presence of both during V(D)J recombination might be detrimental to the survival of the rearranging B or T cell.

Inefficient CJ formation caused by an excess of nucleotide deletion or addition

To determine whether the concomitant expression of two exos adversely affects CJ formation, the standard recombination assay (described above) was performed. In this assay, recombination of the CJ substrate plasmid (the same substrate used in the previous section) activates expression of the chloramphenicol acetyltransferase (CAM) gene by removing the transcriptional terminator that lies between two coding/RS sequences. Plasmids recovered from transfected CHO cells were introduced into bacteria by transformation to determine the relative recombination efficiency by assaying for the ratio of total plasmids recovered (ampicillin-resistant colonies) over recombined plasmids (ampicillin/CAM-resistant colonies). In this assay, the presence of hTdTL2 clearly impaired CJ formation compared with no TdT control (Fig. 6A). In contrast, the overexpression of hTdTL1, which consistently causes a lower level of deletion, did not have a great effect on CJ formation. In addition, hTdTS overexpression effected a similar degree of reduction in CJ formation as hTdTL2. However, the impairment of CJ formation was corrected by the concomitant expression of hTdTS withhTdTL2, but not by the coexpression of all three isoforms, which were expressed at equivalent levels as shown by immunoblotting (Fig. 6B). Together, these data and those shown for human TCR{beta} chain (43) suggest that the uncontrolled elongation (through N addition by hTdTS) or reduction (through nucleotide deletion by hTdTL2) of V(D)J joins or CDR3 length, has the potential to adversely affect V(D)J recombination, thus generating nonproductive BCR or TCR, and reduces the survival of a rearranging B or T cell.



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 6. Inefficient CJ formation caused by an excess of nucleotide deletion or addition. The standard recombination assay was performed as described in Materials and Methods. A, In this assay, recombination of the CJ substrate plasmid activates expression of the CAM gene by removing the transcriptional terminator that lies between two coding/RS sequences. Plasmids recovered from transfected cells were introduced into bacteria via transformation to determine the relative recombination efficiency by assaying for the ratio of total plasmids recovered (ampicillin-resistant colonies) over recombined plasmids (ampicillin/CAM-resistant colonies). B, Immunoblots were done to confirm protein expression. hTdT isoforms were detected with the same rabbit Ab as in Fig. 3.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have shown that humans, like cattle and mice, have three TdT splice variants, hTdTS, hTdTL1, and hTdTL2. hTdTL1 and hTdTL2are derived from mature transcripts that include exons XII and VII, respectively. The amino acid sequences of human L1 and L2 inserts are highly homologous to those of bovine, having 67 and 77% identity, respectively. In contrast, the mL1 insert shows a low degree of amino acid identity to either human or bovine. Moreover, human and bovine L1 inserts are half the size of that of mouse, whereas the L2 insert of human and bovine has approximately the same size as that of mL1 insert. It is puzzling that the amino acid sequence of mL1 insert is so divergent from those of human and bovine inserts, whereas the genomic organization of their TdT genes is conserved. Taken together, these data suggest that the L1 and L2 inserts may serve as structural rather than protein interaction domains, which allow TdTL1 and TdTL2 to assume conformations different from those of TdTS. The change of conformation, in turn, may confer different DNA-modifying activities, i.e., 3'->5' exo activity, to TdTL1 and TdTL2. The lack of nucleotide sequence homology between mouse and human TdTL isoforms may explain why past attempts to clone hTdTL, based on mouse sequences were unsuccessful. It is conceivable that TdT splice variants may also exist in other vertebrate species in which modification of Ig and TCR genes rearrangements is necessary to generate diverse repertoires. Indeed, identification of three TdT splice variants from the rat genomic database, and analysis of the nucleotide sequences shows that the deduced amino acid sequence of rat L1 and L2 inserts are quite divergent from those of mouse (T.-H. Thai and J. F. Kearney, manuscript in preparation). Because of the lack of homology between sequences, the search for TdTL isoforms in other species may be difficult in the absence of a genomic database for the respective species. The nucleotide sequences of our hTdTS, hTdTL1, and hTdTL2 cDNAs are identical with genomic sequences retrieved from both the NCBI and Celera human genome databases, suggesting that there is no polymorphism in the coding exons.

Like mTdTL1, hTdTL2 also possesses 3'->5' exo activity. Furthermore, hTdTL2, consistently expressed during normal B and T lymphocyte development, is devoid of transferase activity, as evidenced by the complete absence of N addition in CJs derived from the recombinants. The inability of hTdTL2 to add nucleotides is corroborated by the in vitro primer modification assay. Thus, in human, hTdTL2 has the same enzymatic qualities as mTdTL1 (23). Although hTdTL1, containing an insert half the size of mTdTL1, is not expressed during normal B and T cell development, it does exhibit 3'->5' exo activity, albeit at a lower level. Unlike hTdTL2, 1 of 16 CJs obtained from hTdTL1 transfectants contains 1 nt (C) that could be derived from N addition. As expected, hTdTS efficiently catalyzes N addition without causing deletion above background. The concomitant expression of hTdTS with either long isoform reduces the average number of nucleotides deleted to background levels, and the coexpression of all three isoforms does not enhance nucleotide removal, suggesting that CJs with extensive deletion were not recovered, because they could not recombine. Therefore, it is likely that, because B and T cells normally express both isoforms during recombination, their Ig and TCR V(D)J junctions would not display a high degree of nucleotide loss. It is noteworthy to point out that the presence of hTdTL2 or hTdTL1 together with hTdTS in CJs does not shorten the length of N regions but diminishes the average nucleotides deleted, suggesting that nucleotide deletion may take place before addition.

The overexpression of either hTdTS or hTdTL2 effects a dramatic reduction in the recombination frequency, which can be rectified by the concomitant expression of these two isoforms in the same cell. However, the presence of the third isoform during CJ formation does not rescue the decrease in recombination frequency, but rather diminishes it. These results demonstrate that there may be a strong evolutionary selection for the coexpression of one transferase (hTdTS) and one exo (hTdTL2), but against the coexpression of two exos during V(D)J joining. This differential expression of the two long isoforms is regulated at the level of mRNA alternative splicing. Alternatively, these results may reflect other physiological activities such as TdTL1 being a regulator of TdTL2 or TdTS. These possibilities are being explored.

hTdTL1 and hTdTL2 localize in the nucleus, and, like hTdTS, hTdTL2 is expressed in pro-B and pre-B stages of B cell development; a minuscule amount of hTdTL1 transcript is detected in this stage. However, hTdTL1 transcripts are readily detected in transformed cells representative of pre-B cells. The expression pattern of hTdTS (transferase) and hTdTL2 (exo) in pre-B cells is consistent with data showing that human L chains sustain N addition as well as nucleotide deletion (43, 44, 45, 46, 47, 48, 49).

Both hTdTS and hTdTL2 are coexpressed in all thymocyte subpopulations (DN, DP, CD4+, and CD8+) during normal human fetal thymocyte development. However, the level of hTdTL2 expression is higher at fetal day 91, and by fetal day 111, the level of hTdTS has increased, but not to that of hTdTL2. Our data support previous studies demonstrating that the degree of N addition in TCR-{beta} DJ junctions of human fetal thymocytes increases with age, but the extent of nucleotide nibbling remains constant or slightly decreased (50). This decrease of nibbling is probably affected by N addition through the increased expression of hTdTS in adult, as discussed above. The persistent expression of hTdTS and hTdTL2 in all stages of thymocyte development also explains the presence of N addition and nucleotide deletion in human TCR-{beta}, -{alpha}, -{gamma}, and -{delta} chain genes (51, 52, 53, 54, 55).

The absence of hTdTL1 in normal lymphocytes could be due to transcript instability, low abundance, or constitutive splicing of exon XII. In addition, there is no difference in expression levels of hTdTS and hTdTL2 in transformed cells. Thus, hTdT RNA processing and/or steady-state maintenance may be tightly controlled during normal human B and T cell development, and this control is lost upon cellular transformation.

Clinically, hTdT has been used as a marker for the diagnosis of leukemias due to its abundant expression. Until now, the presence of long isoforms has not been described, and a full understanding of the consequences of TdT isoform overexpression has not been explored. One possible outcome of hTdT isoform overexpression is that, in leukemias as in many other tumors, cells undergo a high rate of DNA synthesis and cellular proliferation, thus supplying a large pool of DNA breaks as substrates for hTdT isoform modification. This unwarranted modification by hTdT isoforms may create damages in the genome, which, in turn, activates cell cycle checkpoints to arrest DNA replication and mitosis. The recruitment of hTdT isoforms to sites of DNA damage may be mediated by BRCT-BRCT interactions (56). A second undesirable consequence of the deregulation of hTdT isoform expression is the decrease of V(D)J recombination events that may lead to reduced number of cells expressing functional receptors. Thus, hTdT isoform overexpression during leukemogenesis may have more severe consequences on the maintenance and/or dissemination of the tumor. The nucleoside analog cordycepin has been shown to be highly cytotoxic against TdT+ but not TdT– cells in vitro in the presence of adenosine deaminase inhibitors such as coformycin (57, 58, 59). However, the mechanisms by which these drugs exert their cytotoxicity exclusively on TdT+ cells are not understood. The identification and functional characterization of hTdT isoforms may offer insights into the mechanism of actions of these drugs, thus aiding in the design of more effective treatments for certain types of TdT+ acute lymphocytic leukemia cells and chronic myelogenous leukemic cells in blast crisis. Finally, analyses of newly discovered hTdTL1 and -2 isoforms should be incorporated into future diagnoses of human leukemias.


   Acknowledgments
 
We thank D. B. Roth for help with the recombination assay and for the generous gift of truncated-core RAG1 and -2 (pMS127 and pMS216E, respectively) and substrate plasmids (pJH289-signal join and pJH290-coding join), and the CHO cell line RMP41. We thank the Birth Defects Research Laboratory at University of Washington for providing human thymi, and University of Alabama at Birmingham Cancer Center Tissue Procurement program for human bone marrows. We also thank M. Ehrensteinfor hTdTS cDNA, L. Gartland for sorting, X. Y. Liu for technical assistance, D. McPherson and the CFAR molecular biology core facility for advice on cloning hTdTL1 and hTdTL2, and A. Brookshire for preparing this manuscript.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health (NIH) Grant AI 523133. T.-H.T. is supported by NIH Grant T32AI07051-26, and the Center for AIDS Research core facility is supported by NIH Grant AI 123456. University of Alabama at Birmingham Cancer Center Tissue Procurement Program was supported by NIH Grant CA 13148. Back

2 Current address: Center for Blood Research Institute for Biomedical Research, Inc., Harvard Medical School, 138 Warren Alpert Building, Boston, MA 02115. Back

3 Address correspondence and reprint requests to Dr. John F. Kearney, University of Alabama at Birmingham, 378 Wallace Tumor Institute, 1824 Sixth Avenue South, Birmingham, AL 35294-3300. E-mail address: jfk{at}uab.edu Back

4 Abbreviations used in this paper: N, nontemplated; P, palindromic; m, mouse; h, human; b, bovine; S, short isoform; L, long isoform; exo, exonuclease; BRCT, BRCA-1 C-terminal; s, surface; DN, double-negative; DP, double-positive; CJ, coding join; CAM, chloramphenicol acetyltransferase. Back

Received for publication March 29, 2004. Accepted for publication July 13, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Gilfillan, S., C. Benoist, D. Mathis. 1995. Mice lacking terminal deoxynucleotidyl transferase: adult mice with a fetal antigen receptor repertoire. Immunol. Rev. 148:201.[Medline]
  2. Tjoelker, L. W., L. M. Carlson, K. Lee, J. Lahti, W. T. McCormack, J. M. Leiden, C. L. Chen, M. D. Cooper, C. B. Thompson. 1990. Evolutionary conservation of antigen recognition: the chicken T-cell receptor {beta} chain. Proc. Natl. Acad. Sci. USA 87:7856.[Abstract/Free Full Text]
  3. Turchin, A., E. Hsu. 1996. The generation of antibody diversity in the turtle. J. Immunol. 156:3797.[Abstract]
  4. Kerfoun, F., J. Charlemagne, J. S. Fellah. 1996. The structure, rearrangement, and ontogenic expression of DB and JB gene segments of the Mexican axolotl T-cell antigen receptor {beta} chain (TCRB). Immunogenetics 44:275.[Medline]
  5. Partula, S., A. de Guerra, J. S. Fellah, J. Charlemagne. 1996. Structure and diversity of the TCR {alpha}-chain in a teleost fish. J. Immunol. 157:207.[Abstract]
  6. Hawke, N. A., J. P. Rast, G. W. Litman. 1996. Extensive diversity of transcribed TCR-{beta} in a phylogenetically primitive vertebrate. J. Immunol. 156:2458.[Abstract]
  7. Hozumi, N., S. Tonegawa. 1976. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc. Natl. Acad. Sci. USA 73:3628.[Abstract/Free Full Text]
  8. Melchers, F., A. Rolink, U. Grawunder, T. H. Winkler, H. Karasuyama, P. Ghia, J. Andersson. 1995. Positive and negative selection events during B lymphopoiesis. Curr. Opin. Immunol. 7:214.[Medline]
  9. Lewis, M. S.. 1994. The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv. Immunol. 56:127.
  10. Fugmann, S. D., A. I. Lee, P. E. Shockett, I. J. Villey, D. G. Schatz. 2000. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu. Rev. Immunol. 18:497.
  11. Oettinger, M. A.. 1999. V(D)J recombination: on the cutting edge. Curr. Opin. Cell Biol. 11:325.[Medline]
  12. Nicolas, N., D. Moshous, M. Cavazzana-Calvo, D. Papadopoulo, R. de Chasseval, F. Le Deist, A. Fischer, J-P. de Villartay. 1998. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J. Exp. Med. 188:627.[Abstract/Free Full Text]
  13. Moshous, D., I. Callebaut, R. de Chasseval, B. Corneo, M. Cavazzana-Calvo, F. Le Deist, I. Tezcan, O. Sanal, Y. Bertrand, N. Philippe, et al 2001. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105:177.[Medline]
  14. Ma, Y., U. Pannicke, K. Schwarz, M. R. Lieber. 2002. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108:781.[Medline]
  15. Rooney, S., F. W. Alt, D. Lombard, S. Whitlow, M. Eckersdorff, J. Fleming, S. Fugmann, D. O. Ferguson, D. G. Schatz, J. Sekiguchi. 2003. Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J. Exp. Med. 197:553.[Abstract/Free Full Text]
  16. Arstila, T. P., A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, P. Kourilsky. 1999. A direct estimate of the human {alpha}{beta} T cell receptor diversity. Science 286:958.[Abstract/Free Full Text]
  17. Cabaniols, J. P., N. Fazilleau, A. Casrouge, P. Kourilsky, J. M. Kanellopoulos. 2001. Most {alpha}{beta} T cell receptor diversity is due to terminal deoxynucleotidyl transferase. J. Exp. Med. 194:1385.[Abstract/Free Full Text]
  18. Komori, T., A. Okada, V. Stewart, F. W. Alt. 1993. Lack of N regions in antigen receptor variable region genes of TdT-deficient lymphocytes. Science 261:1171.[Abstract/Free Full Text]
  19. Gilfillan, S., A. Dierich, M. Lemeur, C. Benoist, D. Mathis. 1993. Mice lacking TdT: mature animals with an immature lymphocyte repertoire. Science 261:1175.[Abstract/Free Full Text]
  20. Doyen, N., M. F. d’Andon, L. A. Bentolila, Q. T. Nguyen, E. Rougeon. 1993. Differential splicing in mouse thymus generates two forms of terminal deoxynucleotidyl transferase. Nucleic Acids Res. 21:1187.[Abstract/Free Full Text]
  21. Benedict, C. L., J. F. Kearney. 1999. Increased junctional diversity in fetal B cells results in a loss of protective anti-phosphorylcholine antibodies in adult mice. Immunity 5:607.
  22. Bentolila, L. A., M. Fanton d’Andon, Q. T. Nguyen, O. Martinez, F. Rougeon, N. Doyen. 1995. The two isoforms of mouse terminal deoxynucleotidyl transferase differ in both the ability to add N regions and subcellular localization. EMBO J. 14:4221.[Medline]
  23. Thai, T.-H., M. M. Purugganan, D. B. Roth, J. F. Kearney. 2002. Distinct and opposite diversifying activities of terminal transferase splice variants. Nat. Immunol. 3:457.[Medline]
  24. Koiwai, O, T. Yokota, T. Kageyama, T. Hirose, S. K. Yoshida, K. Arai. 1986. Isolation and characterization of bovine and mouse terminal deoxynucleotidyl transferase cDNAs expressible in mammalian cells. Nucleic Acids Res. 14:5777.[Abstract/Free Full Text]
  25. Lee, A., E. Hsu. 1994. Isolation and characterization of the Xenopus terminal deoxynucleotidyltransferase. J. Immunol. 152:4500.[Abstract]
  26. Yang, B., K. N. Gathy, M. S. Coleman. 1995. T-cell specific avian TdT: characterization of the cDNA and recombinant enzyme. Nucleic Acids Res. 23:2041.[Abstract/Free Full Text]
  27. Hansen, J. D.. 1997. Characterization of rainbow trout terminal deoxynucleotidyl transferase structure and expression: TdT and RAG1 co-expression define the trout primary lymphoid tissues. Immunogenetics 46:367.[Medline]
  28. Takahara, K., N. Hayashi, K. Fujita-Sagawa, T. Morishita, Y. Hashimoto, A. Noda. 1994. Alternative splicing of bovine terminal deoxynucleotidyl transferase cDNA. Biosci. Biotech. Biochem. 58:786.[Medline]
  29. Girschick, H. J., A. C. Grammer, T. Nanki, M. Mayo, P. E. Lipsky. 2001. RAG1 and RAG2 expression by B cell subsets from human tonsil and peripheral blood. J. Immunol. 166:377.[Abstract/Free Full Text]
  30. Dominguez, O., J. F. Ruiz, T. Lain de Lera, M. Garcia-Diaz, M. A. Gonzalez, T. Kirchhoff, A. C. Martinez, A. Bernad, L. Blanco. 2000. DNA polymerase µ (Pol µ), homologous to TdT, could act as a DNA mutator in eukaryotic cells. EMBO J. 19:1731.[Medline]
  31. Aoufouchi, S., E. Flatter, A. Dahan, A. Faili, B. Bertocci, S. Storck, F. Delbos, L. Cocea, N. Gupta, J. C. Weill, C. A. Reynaud. 2000. Two novel human and mouse DNA polymerases of the polX family. Nucleic Acids Res. 28:3684.[Abstract/Free Full Text]
  32. Hoffbrand, A. V., K. Ganeshaguru, G. Janossy, M. F. Greaves, D. Catovsky, R. K. Woodruff. 1977. Terminal deoxynucleotidyl-transferase levels and membrane phenotypes in diagnosis of acute leukemia. Lancet 2:520.[Medline]
  33. Kung, P. C., J. C. Long, R. P. McCaffrey, R. L. Ratliff, T. A. Harrison, D. Baltimore. 1978. Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. Am. J. Med. 64:788.[Medline]
  34. Greaves, M., D. Delia, G. Janossy, N. Rapson, J. Chessells, M. Woods, G. Prentice. 1980. Acute lymphoblastic leukemia associated antigen. III. Alterations in expression during treatment and in relapse. Leukemia Res. 4:1.[Medline]
  35. Riley, L. K., J. K. Morrow, M. J. Danton, M. S. Coleman. 1988. Human terminal deoxyribonucleotidyltranferase: molecular cloning and structural analysis of the gene and 5' flanking region. Proc. Natl. Acad. Sci. USA 85:2489.[Abstract/Free Full Text]
  36. Callebaut, I., J.-P. Mornon. 1997. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 400:25.[Medline]
  37. Huyton, T., P. A. Bates, X. Zhang, M. J. Sternberg, P. S. Freemont. 2000. The BRCA1 C-terminal domain: structure and function. Mutat. Res. 460:319.[Medline]
  38. Deibel, M. R., M. S. Coleman, K. Acree. 1981. Biochemical and immunological properties of human terminal deoxynucleotidyl transferase purified from blasts of acute lymphoblastic and chronic myelogenous leukemia. J. Clin. Invest. 67:725.
  39. Peterson, R. C., L. C. Cheung, R. J. Mattaliano, L. M. Chang, F. J. Bollum. 1984. Molecular cloning of human terminal deoxynucleotidyl transferase. Proc. Natl. Acad. Sci. USA 81:4363.[Abstract/Free Full Text]
  40. Farrar, Y. J., R. B. Evans, C. M. Beach, M. S. Coleman. 1991. Interactions of photoreactive DNAs with terminal deoxynucleotidyl transferase: identification of peptides in the DNA binding domain. Biochemistry 30:3075.[Medline]
  41. Yang, B., K. N. Gathy, M. S. Coleman. 1994. Mutational analysis of residues in the nucleotide binding domain of human terminal deoxynucleotidyl transferase. J. Biol. Chem. 269:11859.[Abstract/Free Full Text]
  42. Ghia, P., E. ten Boekel, E. Sanz, A. de la Hera, A. Rolink, F. Melchers. 1996. Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci. J. Exp. Med. 184:2217.[Abstract/Free Full Text]
  43. Manfras, B. J., D. Terjunk, B. O. Boehm. 1990. Non-productive human TCR {beta} chain genes represent V-D-J diversity before selection upon function: insight into biased usage of TCR{beta}D and TCR{beta}J genes and diversity of CDR3 region length. Hum. Immunol. 60:1090.
  44. Martin, T., G. Blaison, H. Levallois, J. L. Pasquali. 1992. Molecular analysis of the V{kappa}III-J{kappa} junctional diversity of polyclonal rheumatoid factors during rheumatoid arthritis frequently reveals N addition. Eur. J. Immunol. 22:1773.[Medline]
  45. Klein, R., R. Jaenichen, H. G. Zachau. 1993. Expressed human immunoglobulin {kappa} genes and their hypermutation. Eur. J. Immunol. 23:3248.[Medline]
  46. Bridges, S. L., Jr, S. K. Lee, M. L. Johnson, J. C. Lavelle, P. G. Fowler, W. J. Koopman, H. W. Schroeder, Jr. 1995. Somatic mutation and CDR3 lengths of immunoglobulin {kappa} light chains expressed in patients with rheumatoid arthritis and in normal individuals. J. Clin. Invest. 96:832.
  47. Bridges, S. L., Jr. 1998. Frequent N addition and clonal relatedness among immunoglobulin lambda light chains expressed in rheumatoid arthritis synovia and PBL, and the influence of V{lambda} gene segment utilization on CDR3 length. Mol. Med. 4:525.[Medline]
  48. Klein, U., K. Rajewsky, R. Kuppers. 1999. Phenotypic and molecular characterization of human peripheral blood B-cell subsets with special reference to N-region addition and J{kappa}-usage in V{kappa}J{kappa}-joints and {kappa}/{lambda}-ratios in naive versus memory B-cell subsets to identify traces of receptor editing processes. Curr. Top. Microbiol. Immunol. 246:141.[Medline]
  49. Girschick, H. J., P. E. Lipsky. 2001. The {kappa} gene repertoire of human neonatal B cells. Mol. Immunol. 38:1113.
  50. George, J. F., H. W. Schroeder. 1992. Developmental regulation of D{beta} reading frame and junctional diversity in T cell receptor-{beta} transcripts from human thymus. J. Immunol. 148:1230.[Abstract]
  51. Yoshikai, Y., N. Kimura, B. Toyonaga, T. W. Mak. 1986. Sequences and repertoire of human T cell receptor {alpha} chain variable region genes in mature T lymphocytes. J. Exp. Med. 164:90.[Abstract/Free Full Text]
  52. Dave, V. P., M. Larché, S. D. Rencher, B. F. Koop, J. L. Hurwitz. 1993. Restricted usage of T-cell receptor V{alpha} sequence and variable-joining pairs after normal T-cell development and bone marrow transplanstation. Hum. Immunol. 37:178.[Medline]
  53. Genevée, C., V. Chung, A. Diu, T. Hercend, F. Triebel. 1994. TCR gene segments from at least one third of V{alpha} subfamilies rearrange at the {delta} locus. Mol. Immunol. 31:109.[Medline]
  54. Breit, T. M., J. J. M. Van Dongen. 1994. Unraveling human T-cell receptor junctional region sequences. Thymus 22:177.[Medline]
  55. Roldan, E. Q., A. Sottini, A. Bettinardi, A. Albertini, L. Imberti, D. Primi. 1995. Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells. Immunogenetics 41:91.[Medline]
  56. Mahajan, K. N., B. S. Mitchell. 2003. Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc. Natl. Acad. Sci. USA 100:10746.[Abstract/Free Full Text]
  57. Koç, Y., R. McCaffrey. 1995. 2',3'-Dideoxyadenosine killing of TdT-positive cells is due to trace contaminant. Leukemia 9:53.[Medline]
  58. Koç, Y., A. G. Urbano, E. B. Sweeney, R. McCaffrey. 1996. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Leukemia 10:1019.[Medline]
  59. Kodama, E. N., R. P. McCaffrey, K. Yusa, H. Mitsuya. 2000. Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem. Pharmacol. 59:273.[Medline]



This article has been cited by other articles:


Home page
 GENES CELLSHome page
S. Maezawa, T. Hayano, K. Koiwai, R. Fukushima, K. Kouda, T. Kubota, and O. Koiwai
Bood POZ containing gene type 2 is a human counterpart of yeast Btb3p and promotes the degradation of terminal deoxynucleotidyltransferase.
Genes Cells, May 1, 2008; 13(5): 439 - 457.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Murray, J. P. O'Neill, T. Messier, J. Rivers, V. E. Walker, B. McGonagle, L. Trombley, L. G. Cowell, G. Kelsoe, F. McBlane, et al.
V(D)J Recombinase-Mediated Processing of Coding Junctions at Cryptic Recombination Signal Sequences in Peripheral T Cells during Human Development
J. Immunol., October 15, 2006; 177(8): 5393 - 5404.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Wang, B. Yan, J.-t. Guo, C. Hicks, and Y. Xu
Structural genomics analysis of alternative splicing and application to isoform structure modeling
PNAS, December 27, 2005; 102(52): 18920 - 18925.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thai, T.-H.
Right arrow Articles by Kearney, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thai, T.-H.
Right arrow Articles by Kearney, J. F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS